KPV: The Alpha-MSH Tripeptide and What Inflammation Research Actually Shows

KPV is three amino acids long. That is the whole molecule: lysine, proline, valine, the C-terminal tail of α-melanocyte-stimulating hormone. Peptide catalogs sell it as a gut-calming, skin-calming, “anti-inflammatory” research compound. The rodent colitis papers are real, the uptake story is more interesting than the marketing, and there are still no randomized trials of KPV given to humans.

TL;DR

• KPV is residues 11 to 13 of α-MSH: Lys-Pro-Val. It keeps anti-inflammatory activity in animal models without the pigmentation effects of the parent hormone.
• It probably does not work as a classical melanocortin-receptor agonist. A 2003 peritonitis study broke that assumption.
• The strongest data are gut data: uptake through the PepT1 transporter, NF-κB suppression in cells, and improvement in two mouse colitis models.
• Getting a free tripeptide to the colon intact is still an open delivery problem. The best result came from nanoparticles, not a plain vial.
• No human trials exist. In 2026 FDA staff proposed not adding KPV to the 503A compounding bulks list.

Educational only. Not medical advice, not a protocol, and not a reason to treat research vials as IBD therapy.

What KPV actually is

α-MSH is a 13-residue melanocortin peptide. Residues 11 to 13 are Lys-Pro-Val. Strip the rest of the hormone away and you still have anti-inflammatory activity in several animal models, without the pigmentation program that made the parent peptide famous.

That is a different object from bremelanotide, the cyclic melanocortin agonist approved as Vyleesi. Bremelanotide is an MC4R drug with human phase 3 data and a label. KPV is a linear tripeptide with a two-decade preclinical trail and no approved indication.

One naming trap worth knowing: “KPV” is a common name, not a USAN. Free base and acetate are different bulk drug substances. FDA staff spent part of a 2026 compounding briefing pointing that out, because catalogs often do not.

Does KPV work through melanocortin receptors?

Probably not, and that is the most interesting thing about it.

The obvious guess is that KPV lights up the same melanocortin receptors as α-MSH. Getting, Schiöth, and Perretti tested that in crystal-induced peritonitis in 2003. Systemic KPV reduced neutrophil accumulation, and so did α-MSH, the core tetrapeptide His-Phe-Arg-Trp, and the MC3/4 agonist MTII.

The resemblance stopped there:

• The MC3/4 antagonist SHU9119 did not block KPV.
• KPV did not raise macrophage cAMP.
• KPV did not suppress macrophage release of KC and IL-1β the way α-MSH and MTII did.
• The anti-migratory effect still appeared in IL-1β-driven peritonitis, and in recessive-yellow mice that lack functional MC1R.

Source: Getting et al., Journal of Pharmacology and Experimental Therapeutics, 2003.

The C-terminal fragment does not behave like the core MSH peptides. The better working model is interference with IL-1β signaling. Two independent colitis groups then took that idea into the gut.

Why PepT1 is the reason oral KPV makes sense

PepT1 (SLC15A1) is a proton-coupled di/tripeptide transporter. In healthy tissue it lives mainly in small-intestine epithelium. In IBD, it is induced in the colon.

That is a delivery handle. A tripeptide that inflamed gut tissue is already primed to take up.

Dalmasso and colleagues at Emory showed that nanomolar KPV inhibits NF-κB and MAP-kinase activation and cuts pro-inflammatory cytokine secretion in Caco2-BBE and HT29-Cl.19A epithelial cells and in Jurkat T cells. Uptake competed with known PepT1 substrates. Knock the transporter down, and the anti-inflammatory effect goes with it.

In mice, KPV in drinking water reduced histologic injury and colonic cytokine mRNA in both DSS and TNBS colitis (Dalmasso et al., Gastroenterology, 2008).

That paper is why serious discussion of KPV starts with transport, not with a receptor cartoon.

What the two colitis models showed

Kannengiesser’s Münster group ran KPV in DSS colitis and in CD45RB-high T-cell transfer colitis.

• DSS colitis: treated mice recovered earlier, regained more weight, and showed fewer histologic infiltrates and lower myeloperoxidase activity.
• Transfer colitis: results moved in the same direction.
• MC1R-deficient mice (MC1R^e/e): KPV rescued every animal in the treatment group from death during DSS colitis.

Source: Kannengiesser et al., Inflammatory Bowel Diseases, 2008.

Partial MC1R independence in a lethal DSS model lines up with Getting’s peritonitis work. It does not prove a human indication. DSS and transfer colitis are tools, not Crohn’s disease or ulcerative colitis.

A 2023 review in Cells put KPV and the related analog KdPT back into the melanocortin-IBD literature and argued the system is still a legitimate drug-discovery surface (Gravina et al., 2023). That is a fair reading of the mouse data. It is not a substitute for a trial.

The evidence at a glance

Getting it to the colon intact is still a research problem

A free tripeptide in drinking water is not a pharmaceutical product.

In 2017, Xiao, Merlin, and colleagues loaded KPV into hyaluronic-acid-functionalized nanoparticles (roughly 272 nm), then packed those particles into a chitosan/alginate hydrogel. The construct targeted colonic epithelial cells and macrophages, lowered TNF-α, and protected mucosa in a mouse colitis model better than a non-targeted KPV nanoparticle hydrogel (Xiao et al., Molecular Therapy, 2017).

That is a delivery study. It is also the clearest illustration of why a research vial is not the same pharmacokinetics.

What FDA actually put on paper

KPV is not an FDA-approved drug. There is no USP or NF monograph, and it is not a component of an approved product.

For the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA evaluated KPV free base and KPV acetate as nominated 503A bulk substances for wound healing and inflammatory conditions, as a 0.1% cream or gel. The original nomination was withdrawn, and the agency reviewed both forms on its own initiative.

Staff concluded:

• The substances are not well-characterized.
• Compounding use is unknown.
• They could not find any study of KPV administered to humans by any route.
• FAERS through December 3, 2025 returned no reports. That is an empty database, not a safety trial, when there is no identified human exposure.

On balance, FDA proposed not adding either form to the 503A Bulks List (FDA PCAC briefing, 2026).

Two caveats cut the other way. Committee advice is non-binding, and a proposal is not a final list decision. A list decision would still not be an approval. Same fork as our 503A/503B compounding landscape: interesting pharmacology does not mint a compounded drug.

How to read the research-peptide conversation

KPV sits next to BPC-157 in a lot of “gut peptide” threads. They are not interchangeable. BPC-157 is a gastric pentadecapeptide with its own mostly preclinical trail. KPV is an α-MSH fragment whose cleanest data are PepT1-dependent NF-κB suppression and two mouse colitis models.

What the evidence supports: KPV changes histology, myeloperoxidase, and cytokine signaling in rodent colitis, and it does so at least partly outside the classical melanocortin receptors.

What it does not support: that research-grade KPV treats IBD, eczema, or “systemic inflammation” in people, or that a topical cream reaches the cells the nanoparticle paper spent years trying to reach.

Sourcing still matters. A certificate of analysis is the minimum filter, not a clinical endorsement, and the name on the vial may not tell you free base versus acetate.

• Compare listed compounds on the Price Index.
• Prefer licensed clinics over research vendors: start with the provider directory.
• Want the class-level primer first? Read Peptides 101.

Bottom line: KPV has a real, twenty-year preclinical story and a genuinely clever uptake mechanism. It has zero human trials and an unsolved delivery problem. Treat the mouse data as a reason to watch the science, not as a protocol.

This article is for educational purposes only and does not constitute medical advice. KPV is not an FDA-approved drug. Research-grade material is not a substitute for approved therapies for inflammatory bowel disease, wounds, or dermatologic disease. Consult a qualified clinician before considering any peptide.